References of "Thonnard, Anne-Sophie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMutations AIP chez les jeunes patients en dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in Annales d'Endocrinologie (2010, September), 71(5), 397

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailDeux nouvelles mutations dans le gène du récepteur du calcium (CASR) entraînant respectivement une hypo- et une hypercalcémie
Thonnard, Anne-Sophie ULg; Livadariu, Elena ULg; Rydlewski, C. et al

in Annales d'Endocrinologie (2010, September), 71(5), 367

Detailed reference viewed: 22 (5 ULg)
Full Text
Peer Reviewed
See detailEtude génétique et anatomopathologique du syndrome de McCune-Albright chez l'adulte
Beckers, Albert ULg; Burlacu, Maria Cristina ULg; Thiry, Albert ULg et al

in Annales d'Endocrinologie (2010, September), 71(5), 345

Detailed reference viewed: 13 (1 ULg)
Full Text
See detailMutations AIP chez les jeunes patients en-dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA): analyse de 86 familles
Beckers, Albert ULg; Tichomirowa, M.; Pellegata, N. et al

in Annales d'Endocrinologie (2010, September), 71(5), 398

Detailed reference viewed: 17 (5 ULg)
Full Text
See detailCaractéristiques cliniques et réponses thérapeutiques des patients avec adénome hypophysaire mutés pour AIP : étude internationale sur 96 cas
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 12 (2 ULg)
Full Text
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA) : analyse de 86 familles
Beckers, Albert ULg; Tichomirowa, M.; Pellegata, N. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 24 (10 ULg)
Full Text
See detailDeux nouvelles mutations dans le gène du récepteur du calcium (CASR) entraînant respectivement une hypo- et une hypercalcémie
Thonnard, Anne-Sophie ULg; Livadariu, E.; Rydlewski, C. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailMedical Treatment in Cushing’s Syndrome : Dopamine Agonists and Cabergoline
Petrossians, Patrick ULg; Thonnard, Anne-Sophie ULg; Beckers, Albert ULg

in Neuroendocrinology (2010), 92((supp. 1)), 116-19

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also ... [more ▼]

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also appear in a number of secretory tumors in various locations, DA agonists have elicited some interest as a medical treatment for hypercorticism. Non-iatrogenic Cushing’s syndromes are due in 70% of the cases to a pituitary adrenocorticotropic hormone (ACTH) producing adenoma, and, less frequently, to an adrenal adenoma or an ectopic ACTH secretion by a neuroendocrine tumor. First-line treatment in Cushing’s syndrome consists of the surgical removal of the secreting tumor. However, surgery may not achieve a complete cure in a number of cases, hence emphasizing the potential benefit of a medical complementary treatment, which could also benefit patients as an alternative approach, either when waiting for, or when the patient is not eligible for surgery. Studies of corticotropic adenomas have shown that 80% of these tumors express D2 receptors. Clinical trials of DA agonists in Cushing’s disease have shown an inhibitory effect of these drugs with an inhibition of ACTH secretion and/or a decrease of tumor size. There are only a few cases of documented use of DA agonists in ectopic ACTH secretion, but when the tumor expresses DA receptors, DA agonists may represent a useful complementary treatment. DA receptors are also expressed in normal and tumoral adrenals, suggesting a potential use of DA agonists in Cushing’s syndrome secondary to adrenal tumors. However, clinical data regarding this specific situation are very scarce, maybe due to the relatively high rate of surgical cure of adrenal adenomas. In conclusion, DA agonists represent a potential preparatory or complementary treatment for endogenous Cushing’s syndrome, especially in Cushing’s disease. These compounds may be underused as suggested by the scarce number of publication and case reports in the literature. In the future, association of these drugs with somatostatin analogs may also prove beneficial. [less ▲]

Detailed reference viewed: 32 (6 ULg)
Full Text
See detailEtude génétique et anatomopathologique du syndrome de McCune-Albright chez l'adulte
Beckers, Albert ULg; Burlacu, M.; Thiry, Albert ULg et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 15 (7 ULg)